Biosound Esaote of Indianapolis last month introduced two cardiovascular color flow ultrasound systems. The two new systems, Caris and Megas, were cleared by the Food and Drug Administration last year.Caris, first introduced at the American College of
Biosound Esaote of Indianapolis last month introduced two cardiovascular color flow ultrasound systems. The two new systems, Caris and Megas, were cleared by the Food and Drug Administration last year.
Caris, first introduced at the American College of Cardiology meeting in New Orleans in March, was designed for the mobile market or hospitals that require a second, portable, cardiovascular ultrasound system. Highly portable, Caris is 9 inches high and weighs 35 pounds.
Megas was introduced at this years meeting of the American Society of Echocardiology in Washington, DC, and is aimed at a market segment new to Biosound: the large group, hospital, or clinic that requires a small, low-cost system with phased array cardiovascular technology. According to Biosound, Megas is the only portable phased array cardiovascular ultrasound system in the world. It boasts ASIC and FPGA microcircuitry and uses a 48-pound mainframe. Megas has both conventional and color Doppler, and can be used with a variety of probes, including linear array and convex array technologies.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.